• Home
• Responsibility
• CR Report 2004
• Engagement with stakeholders
• Engagement with investors

Engagement with investors

Investors are taking a growing interest in the corporate responsibility performance of companies, both as a measure of the long-term sustainability of the business and to decide which companies should be included in their Socially Responsible Investment (SRI) funds.

GSK provides information to these investors in a number of ways.

We meet regularly with SRI analysts to discuss CR issues and respond to their requests for information. During 2004 we had more than 40 meetings with these analysts and discussed issues including access to medicines, animal rights, supply chain, sales and marketing ethics and clinical trials.

We also held several events for SRI analysts to meet and discuss issues with senior management:

• our CR day for SRI analysts in London was attended by 28 analysts and 15 senior GSK managers;
• 14 analysts visited our research laboratories in Harlow where they viewed the high throughput chemistry laboratory, the animal research laboratory and viewed some of the new technology introduced as part of our commitment to the 3Rs (see Investor briefing on R&D);
• 13 SRI and mainstream investors visited our Barnard Castle manufacturing site in the UK to find out about quality control and environmental initiatives.

Some investment and research organisations collect performance information via questionnaires. These are used to rate GSK’s CR performance and to vet GSK for inclusion in CR indices. GSK is included in the FTSE4Good and Dow Jones sustainability.

Back to top